Εμφανίζονται 1 - 6 Αποτελέσματα από 6 για την αναζήτηση '"псевдогипертрофии икроножных мышц"', χρόνος αναζήτησης: 0,49δλ Περιορισμός αποτελεσμάτων
  1. 1
    Academic Journal

    Πηγή: Neuromuscular Diseases; Том 5, № 3 (2015); 42-49 ; Нервно-мышечные болезни; Том 5, № 3 (2015); 42-49 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2015-5-3

    Περιγραφή αρχείου: application/pdf

    Relation: https://nmb.abvpress.ru/jour/article/view/123/118; https://nmb.abvpress.ru/jour/article/view/123/146; Дадали Е.Л. Наследственные нервно-мышечные заболевания: диагностика и медико-генетическое консультирование. Автореф. дис. … д-ра мед. наук. М., 1999.; Мальмберг С.А. Наследственные нервно-мышечные заболевания у детей: современные аспекты электрофизиологии, диагностики и лечения. Автореф. дис. … д-ра мед. наук. М., 2000.; Петрухин А.С. Неврология детского возраста. М.: Медицина, 2004.; Matsumura K. LGMD2C, LGMD2D, LGMD2E, LGMD2F. Ryoikibetsu Shokogun Shirizu 2001;35:88–94.; Nonaka I. Muscular dystrophy: advances in research works and therapeutic trials. Rinsho Shinkeigaku 2004;44:901–4.; Nigro Vincenzo, Savarese Marco. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol 2014;33(1):1–12.; http://neuromuscular.wustl.edu/musdist/lg.html; Urtasun M., Saenz A., Roudaut C. et al. Limb- -girdle muscular dystrophy in Guipuzcoa (Basque Country, Spain). Brain 1998;121:1735 –47.; Monckton G., Hoskin V., Warren S. Prevalence and incidence of muscular dystrophy in Alberta, Canada. Clin Genet 1982;21:19–24.; Emery A.E.H. Muscular Duchenne dystrophy. Oxford monographs on medical genetics. Exford: Univ. press, 1987. Vol. 15. 338 p.; de Paula F., Vainzof M., Passos-Bueno M.R. et al. Clinical variability in Calpainopathy – what makes the difference? Eur J Hum Genet 2002;10:825–32.; Рыжкова О.П., Билева Д.С., Дадали Е.Л. и др. Клинико-генетические характеристики поясно-конечностной прогрессирующей мышечной дистрофии 2А типа. Медицинская генетика 2010;9(11):3–10.; Richard I., Broux O., Allamand V. et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995;27:40–4.; Kinbara K., Ishiura S., Tomioka S. et al. Purification of native p94, a muscle-specific calpain, and characterization of its autolysis. Biochem J 1998; 335:589–96.; Piluso G., Politano L., Aurino S. Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2А phenotypes. J Med Genet 2005;42(9):686–93.; Monaco A.P., Bertelson C.J., Middlesworth W. et al. Detection of deletions spannibg the Duchenne muscular dystrophy locus using a tightly linked DNA segment. Nature 1985;316:842–5.; Monaco A.P., Neve R.L., Colletti-Feener C. et al. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986;323:646–50.; Padberg G.W. The muscular dystrophies and dystrophin. Curr Opin Neurol 1993;6(5):688–94.; Emery A.E. Muscular dystrophy into the new millennium. Neuromuscul Disord 2002;12(4):343–9.; Vainzof M., Moreira E.S., Ferraz G. et al. Further evidence for the organisation of the four sarcoglycans proteins within the dystrophin-glycoprotein complex. Eur J Hum Genet 1999;7:251–4.; Ueyama H., Kumamoto T., Fujimoto S. Expression of three calpain isoform genes in human skeletal muscles. J Neurol Sci 1998;155(2):163–9 .; Anderson L.V., Harrison R.M., Pogue R. et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 2000;10:553–5.; Canki-Klain N., Milic A., Kovac B. Prevalence of the 550delA mutation in calpainopathy (LGMD 2A) in Croatia. Am J Med Genet 2004;125(2): 152–6.; Todorova A., Georgieva B., Tournev I. et al. A large deletion and novel point mutations in the calpain 3 gene (CAPN3) in Bulgarian LGMD2A patients. Neurogenetics 2007;8(3):225–9.; Jones H., De Vivo D.C., Darras B.T. Neuromuscular disorders of infancy, childhood and adolescence. A clinician's approach. Oxford: Butterworth-Heinemann, 2003.; Brooke M.H., Fenichel G.M., Griggs R.C. et al . Clinical investigation in Duchenne dystrophy: 2, Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91–103.; Rosalki S.B. Serum enzymes in disease of skeletal muscle. Clin Lab Med 1989;9: 767–81.; Zatz M., Rapaport D., Vainzof M. et al. Serum creatine-kinase (CK) and pyruvatekinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. J NeurolSci 1991;102:190–6.; Шаркова И.В., Дадали Е.Л., Рыжкова О.П., Евдокименков В.Н. Сравнительный Анализ особенностей фенотипов поясно-конечностных мышечных дистрофий 2А и 2I типов. Нервно-мышечные болезни 2013;(2):39–44.; Bushby K.M. Diagnostic criteria for the limb-girdle muscular dystrophies.– Report of the ENMC Consortium on Limb-Girdle Dystrophies. Neuromuscul Disord 1995;5(1):71–4.; Pogoda T.V., Krakhmaleva I.N., Lipatova N.A. et al. High incidence of 550delA mutation of CAPN3 in LGMD2 patients from Russia. Hum Mut 2000: 15:295–300.; Balci B., Aurino S., Haliloglu G. et al. Calpain-3 mutations in Turkey. Eur J Pediatr 2006;165:293–8.; Canki-Klain N., Milic A., Kovac B. Prevalence of the 550delA mutation in calpainopathy (LGMD 2A) in Croatia. Am J Med Genet 2004;125(2):152–6.; Рыжкова О.П. Клинико-молекулярно-генетический анализ изолированных поясно-конечностных дистрофий, являющихся ферментопатиями. Автореф. дис. … канд. мед. наук. М., 2011.; https://nmb.abvpress.ru/jour/article/view/123

  2. 2
    Academic Journal

    Πηγή: Neuromuscular Diseases; № 2 (2013); 39-44 ; Нервно-мышечные болезни; № 2 (2013); 39-44 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2013-0-2

    Περιγραφή αρχείου: application/pdf

    Relation: https://nmb.abvpress.ru/jour/article/view/48/44; Zatz M., de Paula F., Starling A., Vainzof M. The 10 autosomal recessive limbgirdle muscular dystrophies. Neuromuscul Disord 2003;13:532–44.; http: // www.ncbi.nlm.nih.gov.; Richard I., Broux O., Allamand V. et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995;81:27–40.; Urtasun M., Saenz A., Roudaut C. et al. Limbgirdle muscular dystrophy in Guipuzcoa (Basque Country, Spain). Brain 1998;121:1735–47.; de Paula F., Vainzof M., Passos-Bueno M.R. et al. Clinical variability in Calpainopathy − what makes the difference? Eur J Hum Genet 2002;10:825–32.; Рыжкова О.П., Билева Д.С., Дадали Е.Л. и др. Клинико-генетические характеристики поясно-конечностной прогрессирующей мышечной дистрофии 2А типа. Мед генетика 2010;9(11):3–10.; Mercuri E., Sewry C.A., Brown S.C. et al. Congenital muscular dystrophy with secondary merosin deficiency and normal brain MRI: a novel entity. Neuropediatrics 2000;31:186–9.; Brockington M., Yuva Y., Prandini P. et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Molec Genet 2001;10:2851–9.; Driss A., Amouri C., Hamida C.B. et al. A new locus for autosomal recessive limb girdle muscular dystrophy in a large consanguineous Tunisian family maps to chromosome 19q13.3. Neuromusc Disord 2000;10:240–6.; Hanisch F., Grimm D., Zierz S., Deschauer M. Frequency of the FKRP mutation c.826C>A in isolated hyperCKemia and in limb girdle muscular dystrophy type 2 in German patients. J Neurol 2010;257(2):300–1.; Рыжкова О.П., Шаркова И.В., Дадали Е.Л. и др.Клинико-генетический анализ поясно-конечностной мышечной дистрофии 2I типа. Журн неврол и психиатр 2012;(6):55–9.; Passos-Bueno M.R., Moreira E.S., Marie S.K. et al. Main clinical features of the three mapped autosomal recessive limb-girdle muscular dystrophies and es - timated proportion of each form in 13 Brazilian families. J Med Genet 1996;33:97–102.; Fanin M., Duggan D.J., Mostacciuolo M.L. et al. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. J Med Genet 1997;34:973–7.; Vainzof M., Passos-Bueno M.R., Pavanello R.C. et al. Sarcoglycanopathies are responsible for 68 % of severe autosomal recessive limb-girdle muscular dystrophy in the Brazilian population. J Neurol Sci 1999;164:44–9.; Udd B., Kaarianen H., Somer H. Muscular dystrophy with separate clinical phenotypes in a large family. Muscle Nerve 1991;14:1050–8.; Frosk P., Del Bigio M.R., Wrogemann K., Greenberg C.R. Hutterite brothers both affected with two forms of limb girdle muscular dystrophy: LGMD2H and LGMD2I. Europ J Hum Genet 2005;13:978–82.; Jarry J., Rioux M.F., Bolduc V. et al. A novel autosomal recessive limb-girdle muscular dystrophy with quadriceps atrophy maps to 11p13-p12. Brain 2007;130:368–80.; Boito C.A., Melacini P., Vianello A. et al. Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2I. Arch Neurol 2005;62:1894–9.; Fanin M., Nascimbeni A.C., Fulizio L. et al. Loss of calpain-3 autocatalytic activ - ity in LGMD2А patients with normal protein expression. Am J Pathol 2003;163:1929–36.; Fanin M., Nascimbeni A.C., Angelini C. Screening of calpain-3 autolytic activity in LGMD muscle.– a functional map of CAPN3 gene mutations. J Med Genet 2007;44:38–43.; Talim B., Ognibene A., Mattioli E. et al. Normal calpain expression in genet - ically confirmed limb-girdle muscular dystrophy type 2A. Neurology 2001;56:692–3.; Yamamoto L.U., Velloso F.J., Lima B.L. et al. Muscle protein alterations in LGMD2I patients with different mutations in the Fukutin-related protein gene. J Histochem Cytochem 2008;56:995–1001.; Дадали Е.Л., Щагина О.А., Тибуркова Т.Б. и др. Особенности клинических проявлений и алгоритмы молекулярно-генетической диагностики генетически гетерогенных вариантов наследственных прогрессирующих мышечных дистрофий. В сб.: Молекулярно-биологические технологии в медицинской практике. Под ред. А.Б. Масленникова. Новосибирск: Арт-Лайн, 2010. Вып. 14. С. 174–183.; Рыжкова О.П., Дадали Е.Л., Щагина О.А. и др. Алгоритмы клинико- молекулярно-генетической диагностики наследственных прогрессирующих мышечных дистрофий. Мед генетика 2011;2:17–23.; https://nmb.abvpress.ru/jour/article/view/48

  3. 3
  4. 4
  5. 5
  6. 6